The trajectory of the erectile dysfunction drug presents a complex picture for those considering investment. While the initial release generated significant gains, the end of its patent opened the avenue to off-brand https://neilrecq878986.atualblog.com/48507730/sildenafil-and-the-pharmaceutical-industry-a-risky-investment